VRDN Q2 2022 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$256,000-76.5% YoY

Gross Profit

-$21M-8381.3% margin

Operating Income

-$30M-11548.4% margin

Net Income

-$29M-11519.9% margin

EPS (Diluted)

$-1.06

QoQ Revenue Growth

+18.5%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$170M

Total Liabilities

$28M

Stockholders' Equity

$142M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$256,000	$1M	-76.5%
Gross Profit	-$21M	-$11M	-87.0%
Operating Income	-$30M	-$18M	-64.3%
Net Income	-$29M	-$18M	-64.2%

Revenue Segments

Collaboration Revenue

$300,000100%